DE3855055D1 - Chemische Blockierung durch Phosphithylierung während der Oligonukleotid-Synthese - Google Patents

Chemische Blockierung durch Phosphithylierung während der Oligonukleotid-Synthese

Info

Publication number
DE3855055D1
DE3855055D1 DE3855055T DE3855055T DE3855055D1 DE 3855055 D1 DE3855055 D1 DE 3855055D1 DE 3855055 T DE3855055 T DE 3855055T DE 3855055 T DE3855055 T DE 3855055T DE 3855055 D1 DE3855055 D1 DE 3855055D1
Authority
DE
Germany
Prior art keywords
phosphithylation
oligonucleotide synthesis
chemical blocking
during oligonucleotide
during
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3855055T
Other languages
English (en)
Other versions
DE3855055T2 (de
Inventor
William Alexander Andrus
J William Efcavitch
Lincoln John Mcbride
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lynx Therapeutics Inc
Original Assignee
Lynx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lynx Therapeutics Inc filed Critical Lynx Therapeutics Inc
Application granted granted Critical
Publication of DE3855055D1 publication Critical patent/DE3855055D1/de
Publication of DE3855055T2 publication Critical patent/DE3855055T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C07F9/142—Esters of phosphorous acids with hydroxyalkyl compounds without further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
DE3855055T 1987-06-04 1988-06-02 Chemische Blockierung durch Phosphithylierung während der Oligonukleotid-Synthese Expired - Fee Related DE3855055T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/058,179 US4816571A (en) 1987-06-04 1987-06-04 Chemical capping by phosphitylation during oligonucleotide synthesis

Publications (2)

Publication Number Publication Date
DE3855055D1 true DE3855055D1 (de) 1996-04-11
DE3855055T2 DE3855055T2 (de) 1996-09-19

Family

ID=22015191

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3855055T Expired - Fee Related DE3855055T2 (de) 1987-06-04 1988-06-02 Chemische Blockierung durch Phosphithylierung während der Oligonukleotid-Synthese

Country Status (4)

Country Link
US (1) US4816571A (de)
EP (1) EP0294196B1 (de)
JP (1) JP2787774B2 (de)
DE (1) DE3855055T2 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262530A (en) * 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) * 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5166387A (en) * 1990-01-12 1992-11-24 Applied Biosystems, Inc. Method of synthesizing sulfurized oligonucleotide analogs with thiuram disulfides
WO1992013629A1 (en) * 1991-01-31 1992-08-20 Wayne State University A method for analyzing an organic sample
US5512668A (en) * 1991-03-06 1996-04-30 Polish Academy Of Sciences Solid phase oligonucleotide synthesis using phospholane intermediates
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
NZ245720A (en) * 1992-01-22 1995-12-21 Hoechst Ag Oligonucleotide analogues; use as gene expression inhibitor or dna probe
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
US5643717A (en) * 1992-12-16 1997-07-01 Hybridon, Inc. Substrate useful for separating modified oligonucleotides
US5627277A (en) * 1992-12-16 1997-05-06 Hybridon, Inc. Method for analyzing oligonucleotide analogs
US5506103A (en) * 1993-11-16 1996-04-09 Hybridon, Inc. Method for detecting charged oligonucleotides in biological fluids
AU1608095A (en) * 1994-01-26 1995-08-15 Hybridon, Inc. Method of detecting sub-ppb levels of oligonucleotides in biological fluids
US5510476A (en) * 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
US5990300A (en) * 1994-09-02 1999-11-23 Andrew C. Hiatt Enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
US5763594A (en) * 1994-09-02 1998-06-09 Andrew C. Hiatt 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
US6232465B1 (en) * 1994-09-02 2001-05-15 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
US5872244A (en) * 1994-09-02 1999-02-16 Andrew C. Hiatt 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
US6214987B1 (en) 1994-09-02 2001-04-10 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides
US5750341A (en) * 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US5705621A (en) * 1995-11-17 1998-01-06 Isis Pharmaceuticals, Inc. Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
US6660233B1 (en) 1996-01-16 2003-12-09 Beckman Coulter, Inc. Analytical biochemistry system with robotically carried bioarray
ES2114504B1 (es) * 1996-09-13 1999-02-01 Univ Madrid Autonoma Metodo para la sintesis enzimatica de desoxioligonucleotidos en soporte solido.
WO1998020018A1 (en) * 1996-11-07 1998-05-14 Novartis Ag Process for the preparation of an oligomeric compound
US5760209A (en) * 1997-03-03 1998-06-02 Isis Pharmaceuticals, Inc. Protecting group for synthesizing oligonucleotide analogs
US5902881A (en) * 1997-03-03 1999-05-11 Isis Pharmaceuticals, Inc. Reagent useful for synthesizing sulfurized oligonucleotide analogs
US7427678B2 (en) 1998-01-08 2008-09-23 Sigma-Aldrich Co. Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method
US6020475A (en) * 1998-02-10 2000-02-01 Isis Pharmeuticals, Inc. Process for the synthesis of oligomeric compounds
US7273933B1 (en) * 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6531590B1 (en) 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6326478B1 (en) 1998-07-08 2001-12-04 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6867294B1 (en) * 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6335437B1 (en) 1998-09-07 2002-01-01 Isis Pharmaceuticals, Inc. Methods for the preparation of conjugated oligomers
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6610842B1 (en) 1999-05-06 2003-08-26 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomers using phosphoramidite compositions
US6451998B1 (en) 1999-10-18 2002-09-17 Agilent Technologies, Inc. Capping and de-capping during oligonucleotide synthesis
US6809195B1 (en) * 2000-08-16 2004-10-26 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotides
EP1412749A4 (de) * 2001-06-28 2006-12-13 Ia Inc Faseroptisches sensorarray
US7098326B2 (en) 2002-01-23 2006-08-29 Sigma-Aldrich Co. Methods for the integrated synthesis and purification of oligonucleotides
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
JP2006505832A (ja) * 2002-02-26 2006-02-16 フアルマシア・コーポレーシヨン 配列決定システム計算機
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
US20050009051A1 (en) * 2002-09-27 2005-01-13 Board Of Regents, The University Of Texas Diagnosis of mould infection
US7247337B1 (en) 2002-12-16 2007-07-24 Agilent Technologies, Inc. Method and apparatus for microarray fabrication
EP1585755B1 (de) 2002-12-31 2015-08-05 Sigma-Aldrich Co. LLC Verfahren und zusammenstellungen für die tandem-synthese von zwei oder mehr oligonukleotiden auf einen festen träger
CA2515779A1 (en) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Contraceptive method and compositions related to proteasomal interference
US20050164211A1 (en) * 2004-01-22 2005-07-28 Hannah Eric C. Carbon nanotube molecular labels
EP2065466B1 (de) 2004-05-28 2014-07-09 Asuragen, Inc. Verfahren und Zusammensetzungen mit MircoRNA
JP4933435B2 (ja) 2004-09-14 2012-05-16 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト 遺伝子ターゲティングに基づくブシンドロール処置方法
EP2281889B1 (de) 2004-11-12 2014-07-30 Asuragen, Inc. Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind
EP1871913A2 (de) 2005-03-25 2008-01-02 Ambion, Inc. Verfahren und zusammensetzungen zur verringerung abundanter rna-transkripte
US7396676B2 (en) 2005-05-31 2008-07-08 Agilent Technologies, Inc. Evanescent wave sensor with attached ligand
AU2007299828C1 (en) 2006-09-19 2014-07-17 Interpace Diagnostics, Llc MicroRNAs differentially expressed in pancreatic diseases and uses thereof
JP2010510964A (ja) 2006-09-19 2010-04-08 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路
CN101675165A (zh) 2006-12-08 2010-03-17 奥斯瑞根公司 Let-7微小rna的功能和靶标
US7858772B2 (en) * 2006-12-22 2010-12-28 Roche Molecular Systems, Inc. Compounds and methods for synthesis and purification of oligonucleotides
WO2009102509A2 (en) 2008-01-10 2009-08-20 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
MX2010008168A (es) 2008-01-25 2011-02-24 P53 Inc Biomarcadores p53.
EP2990487A1 (de) 2008-05-08 2016-03-02 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
CA2743057C (en) 2008-11-07 2019-11-26 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
EP2370568B1 (de) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutanten mit resistenz gegen mek inhibitoren
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
US20110045080A1 (en) * 2009-03-24 2011-02-24 William Marsh Rice University Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
CA2766351C (en) 2009-06-29 2018-02-27 Luminex Corporation Chimeric primers with hairpin conformations and methods of using same
US8309710B2 (en) 2009-06-29 2012-11-13 Agilent Technologies, Inc. Use of N-alkyl imidazole for sulfurization of oligonucleotides with an acetyl disulfide
US8642755B2 (en) 2009-06-30 2014-02-04 Agilent Technologies, Inc. Use of thioacetic acid derivatives in the sulfurization of oligonucleotides with phenylacetyl disulfide
WO2011025905A1 (en) 2009-08-28 2011-03-03 Research Development Foundation Urocortin 2 analogs and uses thereof
WO2011032088A1 (en) 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
EP2515899B1 (de) 2009-12-23 2016-05-25 ARCA biopharma, Inc. Verfahren und zusammensetzungen für herz-kreislauf-erkrankungen und -leiden
US20130078614A1 (en) 2010-02-12 2013-03-28 Yonsei University Wonju Industry-Academic Cooperation Foundation Probe for hpv genotype diagnosis and analysis method thereof
CA2789696C (en) 2010-02-25 2017-11-07 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
EP3214174B1 (de) 2010-03-04 2019-10-16 InteRNA Technologies B.V. Mirna-molekül, das über seine quelle definiert ist, und seine diagnostischen und therapeutischen verwendungen bei mit emt assoziierten krankheiten
US20130131148A1 (en) 2010-04-12 2013-05-23 Noam Shomron Micro-rna for cancer diagnosis, prognosis and therapy
WO2011156588A1 (en) 2010-06-09 2011-12-15 Dana-Farber Cancer Institute, Inc. A mek 1 mutation conferring resistance to raf and mek inhibitors
EP3369817A1 (de) 2010-07-06 2018-09-05 InteRNA Technologies B.V. Mirna und ihre diagnostischen und therapeutischen verwendungen bei erkrankungen und zuständen im zusammenhang mit melanomen oder bei erkrankungen und zuständen mit einem aktivierten braf-pfad
CA2817882C (en) 2010-11-17 2022-08-23 Asuragen, Inc. Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms
EP2474617A1 (de) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
EP3178932A1 (de) 2011-02-03 2017-06-14 Mirna Therapeutics, Inc. Synthetische mimetika von mir-34
CN105969773A (zh) 2011-02-03 2016-09-28 米尔纳医疗股份有限公司 Mir-124的合成模拟物
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
EP2755663A4 (de) 2011-09-13 2015-10-07 Ottawa Hospital Res Inst Microrna-inhibitoren
US20130157884A1 (en) 2011-10-26 2013-06-20 Asuragen, Inc. Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
EP3369818B1 (de) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna zur behandlung von kopf-hals-karzinom
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
WO2014055117A1 (en) 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
WO2014134179A1 (en) 2013-02-28 2014-09-04 The Board Of Regents Of The University Of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
US9944992B2 (en) 2013-03-15 2018-04-17 The University Of Chicago Methods and compositions related to T-cell activity
CA2929555A1 (en) 2013-11-08 2015-05-14 Baylor Research Institute Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
US11421229B2 (en) 2015-02-20 2022-08-23 Baylor College Of Medicine p63 inactivation for the treatment of heart failure
CA3019635A1 (en) 2016-03-31 2017-10-05 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
EP3512525B1 (de) 2016-09-16 2022-07-27 Bio-Path Holdings, Inc. Kombinationstherapie mit liposomalen antisense-oligonukleotiden
CA3079524A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
JP7018544B2 (ja) 2018-05-25 2022-02-10 アルカ バイオファーマ， インコーポレイテッド 心房細動の処置のためのブシンドロールを伴う方法および組成物
IL302594A (en) 2020-11-09 2023-07-01 1E Therapeutics Ltd Methods based on catalytic sequences for the treatment or prevention of bacterial infections
WO2022144883A2 (en) 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
AU2021411103A1 (en) 2020-12-28 2023-07-13 1E Therapeutics, Ltd. P21 mrna target areas for silencing
JP2024516548A (ja) 2021-04-08 2024-04-16 ジョスリン ダイアビーティス センター インコーポレイテッド 腎機能低下の診断及び予測の方法
CN118047824B (zh) * 2024-04-01 2024-06-28 北京瑞博奥医药科技有限公司 二烷基膦酸在寡核苷酸合成中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates

Also Published As

Publication number Publication date
US4816571A (en) 1989-03-28
DE3855055T2 (de) 1996-09-19
EP0294196A3 (en) 1990-09-12
JPH01100194A (ja) 1989-04-18
EP0294196A2 (de) 1988-12-07
EP0294196B1 (de) 1996-03-06
JP2787774B2 (ja) 1998-08-20

Similar Documents

Publication Publication Date Title
DE3855055D1 (de) Chemische Blockierung durch Phosphithylierung während der Oligonukleotid-Synthese
DK40788D0 (da) Kemiske forbindelser
ATE29726T1 (de) Difluoro antivirale verbindungen.
DE3881970D1 (de) Heterocyclische verbindungen.
ATE100668T1 (de) Chemische formulierungen.
MX22743A (es) Compuestos quimicos.
DE3769049D1 (de) Heterocyclische verbindungen.
DE3873936D1 (de) Lipoxygenasehemmende verbindungen.
DK90788D0 (da) Kemiske forbindelser
DE3874735D1 (de) Insektizide cyclopropyl-substituierte di(aryl)-verbindungen.
DE3675421D1 (de) Lypoxygenasehemmende verbindungen.
NO880809L (no) Antihyperkolesterolemiske tetrazolforbindelser.
NO883226L (no) Nye aluminium-magnesium-hydroksy-forbindelser.
DE68907982D1 (de) Chemische verbindungen.
DE3788928D1 (de) Chemische Verbindungen.
ATE118771T1 (de) Herzschützende tocopherolähnliche verbindungen.
ATE94537T1 (de) Arylpiperazinylalkylenphenylheterocyclische verbindungen.
DE69017970D1 (de) Biozide Verbindungen.
DE69017971D1 (de) Biozide Verbindungen.
DE3381782D1 (de) Bicyclische benzo-kondensierte verbindungen.
DE3578424D1 (de) Quino-benzothiazin-antibakterielle verbindungen.
DE69016122D1 (de) Biozide Verbindungen.
ATE93512T1 (de) Oximino-aether-verbindungen.
DE3854544D1 (de) Pestizide Verbindungen.
DE3878192D1 (de) N-phenyltetrahydrophthalimidverbindungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee